Our Science

For patients with few options, innovation offers hope

At Oncopeptides, we are dedicated to turning research into therapies that change lives. This is how we do it.

0

Clinical programs

0

Ongoing research programs

0

Research collaborations

0

New molecular candidates

Area of focus

Multiple myeloma

Multiple myeloma is an incurable blood cancer. Symptoms like bone pain, fatigue, and infections severely reduce quality of life. Despite advances in treatment, most patients eventually relapse and become resistant to all available therapies, creating a critical need for innovative options.

Our solution

Melflufen: A new way to fight multiple myeloma

Melflufen is the first treatment of its kind, developed to deliver cancer-killing agents directly inside multiple myeloma cells. It uses enzymes in these cells to activate and release its active substance, damaging cancer DNA and helping to stop disease progression.

Latest science news

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

December 31, 2025

Research shows that Pepaxti is effective in high-risk myeloma

November 12, 2025

NKEngage Grant Project Completed

November 11, 2025

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

November 3, 2025

Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH

October 16, 2025

Exceptional long-term responses to Pepaxti – new publication in Journal of Cancer Research and Clinical Oncology

Upcoming congresses

7th European Myeloma Network Meeting

Clarion Congress Hotel, Prague, Czech Republic

12th World Congress on Controversies in Multiple Myeloma (COMy)

Paris, France & Online

Explore our Science

Pipeline

Clinical Programs

Collaboration

Treatment Principles